In vitro competition model exposes preleukemic super competitor clones
Start here
Researchers have built a scalable in vitro clonal competition platform, described in a bioRxiv preprint, to study how early blood cancer precursor clones behave. Using TET2-mutant clones, they found that roughly 10% act as "super competitors," actively and selectively suppressing the expansion of wild-type cells; in some cases the wild-type clones are eliminated entirely. Molecular profiling and functional assays traced this suppression to inhibition of RAC1-GEF signalling, which appears to be a vulnerability specific to wild-type cells. The platform offers a tractable way to observe clonal competition directly and to probe the mechanisms that let certain preleukemic clones gain ground. Published as a preprint on 22 October 2026, the work has not yet undergone peer review, and validation in primary human samples and in vivo systems is still open.
Written by a model from the reports · updated 5 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biorxiv.orgPickA scalable in vitro cell competition model identifies preleukemic super competitor clones
A team has developed a scalable in vitro clonal competition platform, described in a bioRxiv preprint, and found that ~10% of TET2-mutant clones actively and selectively suppress WT cell expansion. In some cases these clones completely eliminate WT clones, and molecular profiling and functional assays point to RAC1-GEF signalling inhibition as a WT cell-specific vulnerability. DOI: https://doi.org/10.64898/2026.10.21.760611
Heat trend for this story
Heat now 6·Peak in the comparable set 7 (Oct 22 22:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.